We are live on ! Find out more
BIOC

Biocept, Inc.
BIOC

Delisted

BIOC was delisted on the 24th of October, 2023.

Back to rankings

25 hedge funds and large institutions have $808K invested in Biocept, Inc. in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more call options, than puts

Call options by funds: $29K | Put options by funds: $10K

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.16% less ownership

Funds ownership: 10.11% → 8.96% (-1.2%)

4% less funds holding

Funds holding: 26 → 25 (-1)

49% less capital invested

Capital invested by funds: $1.57M → $808K (-$764K)

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
8
Closed
4
Calls
$29K
Puts
$10K
Net Calls
+$19K
Net Calls Change
-$87K

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$16.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$7.66K
3
Bank of America
Bank of America
North Carolina
+$397
4
Vanguard Group
Vanguard Group
Pennsylvania
+$265

Top Sellers

Rank Fund Capital Flow
1
GC
Globeflex Capital
California
-$215K
2
Millennium Management
Millennium Management
New York
-$34K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$13K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$5.56K
5
Renaissance Technologies
Renaissance Technologies
New York
-$4.48K

BIOC Hedge Fund Activity: Q4 2022 in Review

25 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q4 2022, worth a combined $808K — down 49% from $1.57M a quarter earlier.

Fund positioning in BIOC was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 8 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $16.9K. The largest seller was Globeflex Capital, exiting entirely with an estimated $215K sold.

  • 25 institutional investors held Biocept, Inc. (BIOC) as of Q4 2022, down from 26 in Q3 2022.
  • Funds reported $808K of Biocept, Inc. stock for Q4 2022, down 49% quarter-over-quarter.
  • 4 funds opened new Biocept, Inc. positions in Q4 2022 and 4 closed out, a net change of 0 holders.
  • The largest Biocept, Inc. buyer in Q4 2022 was Virtu Financial, an estimated $16.9K added.
  • The largest Biocept, Inc. seller in Q4 2022 was Globeflex Capital, an estimated $215K sold.

Based on aggregated 13F filings for Q4 2022.